All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the key considerations in the management of MPN-AP?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MPN Hub spoke with Olatoyosi Sobulo Odenike, The University of Chicago, Chicago, US. We asked, What are the key considerations in the management of MPN in accelerated phase (MPN-AP)?

What are the key considerations in the management of MPN-AP?

Odenike discusses MPN-AP, she mentions allogeneic stem cell transplants and challenges such as short survival rates in patients.

 

Share: